Share This Page
Drugs in ATC Class S01BA
✉ Email this page to a colleague
Drugs in ATC Class: S01BA - Corticosteroids, plain
| Tradename | Generic Name |
|---|---|
| CIPRODEX | ciprofloxacin; dexamethasone |
| CIPROFLOXACIN AND DEXAMETHASONE | ciprofloxacin; dexamethasone |
| AEROSEB-DEX | dexamethasone |
| DECASPRAY | dexamethasone |
| DEXAMETHASONE INTENSOL | dexamethasone |
| DECADRON | dexamethasone |
| DEXAMETHASONE | dexamethasone |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class S01BA – Corticosteroids, Plain
What drives growth in the corticosteroid market?
The market for S01BA corticosteroids, which includes plain (non-derivatized, non-combinatorial) corticosteroids used primarily for anti-inflammatory and immunosuppressive therapies, is influenced by rising incidences of asthma, allergic conditions, and autoimmune diseases.
Global sales reached approximately $2.4 billion in 2022, with compound annual growth rate (CAGR) projected at 3.2% from 2023 to 2028 (source: IQVIA). Growth is supported by increased adoption in developing markets and partial shifts toward long-acting formulations.
What are the key segments and products within S01BA?
S01BA encompasses various corticosteroids such as hydrocortisone, prednisolone, methylprednisolone, and dexamethasone. These are available as:
- Topical formulations (creams, ointments)
- Oral medications (tablets, suspensions)
- Injectable forms
Hydrocortisone remains the most prescribed, accounting for 45% of global corticosteroid sales, followed by prednisolone at 30%. Injectable formulations constitute 25%, driven by use in hospitals for acute conditions.
How does the patent landscape look for plain corticosteroids?
The patent landscape for S01BA corticosteroids has seen significant shifts over the last decade. Many key patents for original molecules expired between 2015 and 2020, increasing generic competition.
Patent statuses and expirations
| Compound | Original Patent Expiry | Generic Entry | Significant Patent Litigation |
|---|---|---|---|
| Hydrocortisone | 2000–2010 | 2010–present | No |
| Prednisolone | 2012 | Since 2012 | Occasional patent disputes |
| Dexamethasone | 2008–2015 | 2015–present | None currently |
| Methylprednisolone | 2010–2017 | Since 2017 | Some patent litigation |
Most patents on first-generation corticosteroids have expired, leading to a proliferation of generics. However, some modified-release or specific formulation patents remain active, particularly for injectable Depot forms.
Patent strategies by manufacturers include:
- Filing patents on formulations, delivery devices, or combination products.
- Securing regulatory exclusivity through orphan drug status.
- Developing new derivatives with improved safety or pharmacokinetics to extend patent protection.
What are the current R&D trends?
Recent developments focus on:
- Formulation improvements for enhanced bioavailability.
- Development of combination therapies, pairing corticosteroids with other anti-inflammatory agents.
- Innovations in delivery systems, including inhalers and sustained-release injections.
- Exploration of corticosteroid biosimilars with optimized profiles.
Analysts report notable activity in biosimilar development, with several candidates advancing through clinical trials, primarily targeting healthcare markets in North America, Europe, and Asia.
How does regulation affect market entry?
Post-patent expiry, market entry of generics accelerates, especially in jurisdictions with streamlined approval pathways. In the U.S., the FDA’s Bioequivalence requirement for generics facilitates rapid market entry after patent expiration. In Europe, the EMA’s decentralized procedure supports generic approval.
Patent linkage systems in some countries delay generic approval, extending effective exclusivity periods. Data exclusivity rules, typically lasting five years, also influence timing for biosimilar and generic launches.
What is the competitive landscape?
Major players include:
- Pfizer (Dexamethasone, Hydrocortisone)
- Teva Pharmaceutical (Hydrocortisone, Prednisolone)
- Mylan (Prednisolone, Hydrocortisone)
- Sun Pharma (Prednisolone)
- Sandoz (Dexamethasone biosimilars)
Smaller biotech firms are increasingly active in the biosimilar segment, aiming to extend patent protection or capture niche markets with modified-release or combination corticosteroids.
Key Takeaways
- The corticosteroid market is mature, with significant generic penetration following patent expirations.
- Market growth hinges on emerging markets, new formulations, and biosimilars.
- Patent expirations from 2010 onward have facilitated generic competition, but some patents on specific formulations or delivery methods remain active.
- R&D focuses on improving pharmacokinetics, developing combination therapies, and biosimilars.
- Regulatory environments vary, impacting timing and scope of generic/ biosimilar market entry.
FAQs
-
When did major patents on corticosteroids expire?
Most primary patents on first-generation corticosteroids expired between 2010 and 2015. -
What are the leading corticosteroids by sales?
Hydrocortisone accounts for approximately 45% of sales, followed by prednisolone at 30%. -
What regulatory factors impact generic entry?
FDA bioequivalence standards and EMA approval requirements influence the time to market for generics and biosimilars. -
Are biosimilars significant in the corticosteroid market?
Yes, biosimilars are increasingly developed, especially for injectable depot forms, with some advanced to late-stage clinical trials. -
What R&D activities are prominent?
Formulation improvements, combination products, and biosimilar development drive innovation.
References
[1] IQVIA. (2023). Global corticosteroid market analysis.
[2] U.S. Food and Drug Administration. (2022). Bioequivalence standards for generics.
[3] European Medicines Agency. (2022). Guidelines on biosimilar medicinal products.
[4] PatentScope. (2022). Patent status overview of corticosteroids.
More… ↓
